z-logo
Premium
Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial
Author(s) -
Labrie Fernand,
Candas Bernard,
Cusan Lionel,
Gomez Jose Luis,
Bélanger Alain,
Brousseau G.,
Chevrette Eric,
Lévesque Jacques
Publication year - 2004
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20017
Subject(s) - medicine , prostate cancer , rectal examination , randomization , cancer , prostate specific antigen , randomized controlled trial , gynecology , prostate , proportional hazards model , prospective cohort study , prostate cancer screening , urology
PURPOSE This clinical trial is aimed at evaluating the impact of prostate cancer screening on cancer‐specific mortality. SUBJECTS AND METHODS Forty‐six thousand four hundred and eighty‐six (46,486) men aged 45–80 years registered in the electoral roll of the Quebec city area were randomized in 1988 between screening and no screening. Screening included measurement of serum prostatic specific antigen (PSA) using 3.0 ng/ml as upper limit of normal and digital rectal examination (DRE) at first visit. At follow‐up visits, serum PSA only was used. RESULTS Seventy‐four (74) deaths from prostate cancer occurred in the 14,231 unscreened controls while 10 deaths were observed in the screened group of 7,348 men during the first 11 years following randomization. Median follow‐up of screened men was 7.93 years. A Cox proportional hazards model of the age at death from prostate cancer shows a 62% reduction ( P  < 0.002, Fisher's exact test) of cause‐specific mortality in the screened men ( P  = 0.005). These results are in agreement with the continuous decrease of prostate cancer mortality observed in North America. © 2004 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here